The ARMC1 Knockout HT29 Polyclonal Cells product comprises a population of CRISPR/Cas9-edited HT29 cells with targeted disruption of the ARMC1 gene. This polyclonal knockout pool, generated through CRISPR/Cas9-mediated genome editing, provides a loss-of-function model to investigate the biological role of ARMC1 in a human colorectal adenocarcinoma background. The heterogeneous polyclonal format enables robust functional studies by averaging clonal variability, making it suitable for assays requiring a mixed knockout population rather than a clonal derivative.
The parental HT29 cell line is a widely employed model of human colorectal adenocarcinoma, isolated from a 44-year-old female patient. These epithelial cells display adherent growth characteristics, harbor a mutant TP53 gene, and exhibit microsatellite stable (MSS) status, reflecting common genetic features of colorectal cancer. HT29 cells are utilized extensively to study intestinal epithelial differentiation, oncogenic signaling, and drug responses, establishing a relevant context for examining the interplay between ARMC1 and colorectal tumor biology.
ARMC1 encodes a nuclear protein containing armadillo repeats that acts as a transcriptional co-regulator for the androgen receptor (AR). In the canonical androgen signaling cascade, ligands such as testosterone and dihydrotestosterone bind to AR, leading to receptor dimerization, nuclear translocation, and association with HSP90. Activated AR recruits coactivators like ARMC1 and SRC-1 at androgen response elements (AREs) within promoters of target genes, including KLK3, TMPRSS2, and cell cycle regulators CCND1 and CDKN1A. Through this interaction, ARMC1 modulates AR-driven transcriptional programs governing cell proliferation, differentiation, and metabolism.
Knockout of ARMC1 in HT29 cells creates a system to dissect AR-mediated gene regulation in colorectal cancer. Since HT29 cells express functional AR, disruption of its co-regulator ARMC1 can help elucidate how androgen signaling intersects with pathways altered by TP53 mutation and microsatellite stability. This model permits investigation of ARMC1-dependent transcriptional effects on growth and crosstalk between nuclear receptor signaling and intestinal epithelial homeostasis, without confounding ARMC1 expression.
Researchers can employ this knockout tool in a range of experimental procedures. Western blotting and RT-qPCR enable confirmation of ARMC1 disruption and quantification of downstream transcripts like KLK3 and CCND1. AR-responsive luciferase reporter assays measure AR transcriptional activity, while co-immunoprecipitation and immunofluorescence probe AR?CARMC1 interactions and subcellular localization. Functional assays, including cell proliferation and flow cytometry-based cell cycle analysis, assess phenotypic consequences. Additionally, the model supports drug response studies with androgen pathway modulators, offering insights into ARMC1??s role in therapeutic sensitivity in colorectal and androgen-sensitive cancers. For detailed inquiries, please contact Ascent Research.
